Abbott: Coronary Disease trials

The registry lists 40 Coronary Disease studies with Abbott as lead sponsor. 0 are open to participants now and 23 have results posted.

Phase 2 2Phase 3 11Phase 4 6No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery LesionsCompletedNCT02229864Not applicableResults posted
• Absorb IV Randomized Controlled TrialCompletedNCT02173379Not applicableResults posted
• A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)CompletedNCT01923740Not applicableResults posted
• XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm StudyCompletedNCT01894152Results posted
• ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.CompletedNCT01759290Results posted
• ABSORB III Randomized Controlled Trial (RCT)CompletedNCT01751906Not applicableResults posted
• XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm StudyCompletedNCT01249027Results posted
• EXCEL Clinical TrialCompletedNCT01205776Not applicableResults posted
• XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)CompletedNCT01178268Phase 4Results posted
• SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)CompletedNCT01171820Phase 4Results posted
• XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)CompletedNCT01120379Results posted
• A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese PopulationCompletedNCT01115933Not applicableResults posted
• XIENCE V® USA Dual Antiplatelet Therapy (DAPT) CohortCompletedNCT01106534Phase 4Results posted
• XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for JapanCompletedNCT01086228Results posted
• ABSORB EXTEND Clinical InvestigationCompletedNCT01023789Not applicableResults posted
• SPIRIT PRIME Clinical TrialCompletedNCT00916370Phase 3Results posted
• ABSORB Clinical Investigation, Cohort BCompletedNCT00856856Not applicableResults posted
• Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the BloodCompletedNCT00639158Phase 3Results posted
• EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel DiseaseCompletedNCT00531011Phase 4Results posted
• Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedNCT00300482Phase 3Results posted
• Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedNCT00300469Phase 3Results posted
• Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodCompletedNCT00300456Phase 3Results posted
• Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.CompletedNCT00300430Phase 3Results posted
• To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated VesselsCompletedNCT01977534
• EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel DiseaseCompletedNCT01310309
• EXCEL Clinical Trial (Universal Registry)CompletedNCT01205789
• Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in FranceCompletedNCT00987506
• Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up PeriodCompletedNCT00882219Phase 3
• Angio-Seal Evolution Device RegistryCompletedNCT00817349
• XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm StudyCompletedNCT00631228
• SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in EuropeCompletedNCT00402272Phase 4
• ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical InvestigationCompletedNCT00300131
• DaVinci Registry(Distinctly Assess Vision in Coronary Intervention)CompletedNCT00243438
• PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic LesionsCompletedNCT00180466
• SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent SystemCompletedNCT00180310Phase 3
• Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary ArteriesCompletedNCT00148356Phase 2/3
• Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary ArteriesCompletedNCT00140101Phase 2
• Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOASTCompletedNCT00082251Phase 3
• Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)CompletedNCT00080275Phase 3
• Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELLCompletedNCT00079638Phase 4